Andrea Camerini
Overview
Explore the profile of Andrea Camerini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
68
Citations
846
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
31.
Tibaldi C, Camerini A, Tiseo M, Mazzoni F, Barbieri F, Vittimberga I, et al.
Br J Cancer
. 2018 Nov;
119(11):1326-1331.
PMID: 30405211
Background: Cytidine deaminase (CDA) plays a crucial role in the degradation of gemcitabine. In our previous retrospective study, CDA enzymatic activity was the strongest prognostic biomarker of the activity and...
32.
Banna G, Camerini A, Bronte G, Anile G, Addeo A, Rundo F, et al.
Anticancer Res
. 2018 Jun;
38(6):3689-3697.
PMID: 29848729
Aim: To explore the feasibility and activity of oral metronomic vinorelbine patients with advanced NSCLC not eligible to standard chemotherapy because of old age (≥70 years), and/or poor Eastern Cooperative...
33.
Canale M, Camerini A, Magnacca M, Del Meglio J, Lilli A, Donati S, et al.
Anatol J Cardiol
. 2018 Apr;
19(4):292-293.
PMID: 29615547
No abstract available.
34.
Santini D, Ratta R, Pantano F, De Lisi D, Maruzzo M, Galli L, et al.
Oncotarget
. 2017 Dec;
8(59):100708-100716.
PMID: 29246014
Locoregional treatment with radical intent should be considered during therapy with targeted agents in patients with metastatic renal cell carcinoma (mRCC) in order to achieve a complete response, especially in...
35.
Canale M, Camerini A, Magnacca M, Del Meglio J, Lilli A, Donati S, et al.
G Ital Cardiol (Rome)
. 2017 Nov;
18(11):760-763.
PMID: 29105670
The burden of cardiac side effects in oncology patients will dramatically increase in the near future as a result of the widespread use of anticancer agents affecting the cardiovascular system,...
36.
Mencoboni M, Filiberti R, Taveggia P, Del Corso L, Del Conte A, Covesnon M, et al.
Anticancer Res
. 2017 May;
37(6):3189-3194.
PMID: 28551663
Background/aim: The optimal therapeutic use of metronomic vinorelbine has not yet been defined. We aimed to assess the safety of metronomic oral vinorelbine in first-line treatment of elderly patients with...
37.
Canale M, Camerini A, Del Meglio J, Salvatori L, Magnacca M, Casolo G
G Ital Cardiol (Rome)
. 2017 May;
18(4):329-330.
PMID: 28492574
No abstract available.
38.
Tiseo M, Boni L, Ambrosio F, Camerini A, Baldini E, Cinieri S, et al.
J Clin Oncol
. 2017 Jan;
35(12):1281-1287.
PMID: 28135143
Purpose Considering promising results in phase II studies, a randomized phase III trial was designed to assess the efficacy of adding bevacizumab to first-line cisplatin plus etoposide for treatment of...
39.
Gridelli C, Camerini A, Pappagallo G, Pennella A, Anzidei M, Bellomi M, et al.
Cancer Imaging
. 2016 Dec;
16(1):44.
PMID: 28031049
Background: The use of antiangiogenic therapy in non-small cell lung cancer (NSCLC) requires thorough evaluation of patient characteristics in order to avoid potential safety issues, particularly pulmonary haemorrhage (PH). The...
40.
Camerini A, Chella A, Mazzoni F, Puccetti C, Donati S, Lunghi A, et al.
J Chemother
. 2016 Oct;
29(1):38-41.
PMID: 27687319
Background: We aimed to explore the use of platinum plus bevacizumab in a real world NSCLC population. Patients And Methods: We retrospectively collected data from patients affected by NS-NSCLC treated...